Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
All content for Lean By Design is the property of Oscar Gonzalez & Lawrence Wong and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...
0207. Fix What Matters Most: Rethinking Workflow Improvement in Biopharma
Lean By Design
56 minutes
3 months ago
0207. Fix What Matters Most: Rethinking Workflow Improvement in Biopharma
Send us a text In this episode, we introduce a new approach to operational excellence, one built for the realities of today’s biopharma landscape. As the industry faces tighter budgets and widespread restructuring, the pressure to “do more with less” has never been higher. But when you can’t fix everything, where should you start? We share how Sigma Lab Consulting helps clients focus on the workflows that matter most—those that, if broken, pose the greatest risk to execution, decision-making,...
Lean By Design
Send us a text In this episode, we discuss the 2025 MassBio Industry Snapshot — an annual report tracking employment trends, investment, real estate, and pipeline activity across the life sciences ecosystem. With talent displacement, funding cuts, and lab vacancies reshaping the landscape, the conversation zeroes in on how biopharma companies should rethink efficiency. Instead of defaulting to layoffs and budget slashing, Lawrence and Oscar explore how operational clarity, thoughtful pr...